Low prevalence of SARS-CoV-2 among pregnant and postpartum patients with universal screening in Seattle, Washington

Sylvia M. LaCourse MD MPH1,2#, Alisa Kachikis MD MSc3#, Michela Blain MD1, LaVone E. Simmons MD3, James A. Mays MD4, Amber D Pattison RN-C MSN5, Carol C. Salerno MD5, Stephen A. McCartney MD PhD3, Nicole M. Kretzer MD PhD5, Rebecca Resnick PhD6, Rosemary L. Shay MD5, Leah M. Savitsky MD5, Anna C. Curtin MD5, Emily M. Huebner MSc6, Kimberly K. Ma MD3, Shani Delaney MD3, Carlos Delgado MD7, Adrienne Schippers RN BSN8, Jeff Munson PhD5, Paul S. Pottinger MD1, Seth Cohen MD1, Santiago Neme MD MPH1, Lori Bourassa PhD MPH1, Andrew Bryan MD PhD4, Alex Greninger MD PhD MS MPhil4, Keith R. Jerome MD PhD3,10, Alison C. Roxby MD MSc1-2, Erica Lokken PhD MS2,5, Edith Cheng MD MS3, Kristina M. Adams Waldorf MD2,5,11##, Jane Hitti MD MPH MHA3##

1Department of Medicine, Division of Allergy and Infectious Diseases, 2Department of Global Health, 3Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, 4Department of Laboratory Medicine, 5Department of Obstetrics and Gynecology, 6University of Washington School of Medicine, 7Department of Anesthesiology and Pain Medicine, 8Infection Prevention and Control, University of Washington Medical Center – Montlake Campus, 9Department of Psychiatry and Behavioral Sciences, 10Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, United States of America

11Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden

# Contributed equally
##Contributed equally
CORRESPONDING AUTHOR: Sylvia M. LaCourse, 325 9th Avenue, Box 359931, Seattle, WA 98104, sylvial2@uw.edu, (Tel) +1 206-616-5978, (Fax) +1 206-543-4818

SUMMARY: We found a low prevalence of SARS-CoV-2 among pregnant and postpartum patients after initiating universal testing at University of Washington-affiliated hospitals using a combination of on-site rapid testing, high throughput centralized testing, and outpatient drive-through screening prior to admission.
ABSTRACT

We found a low prevalence of SARS-CoV-2 (2.7% [5/188]) among pregnant and postpartum patients after initiating universal testing. Prevalence among symptomatic patients (22.2% [4/18]) was similar to initial targeted screening approaches (19.1% [8/42]). Among 170 asymptomatic patients, two were positive or inconclusive, respectively; repeat testing at 24 hours was negative.

KEYWORDS: pregnancy; COVID-19; SARS-CoV-2; universal screening; viral shedding
Introduction
To date, most COVID-19 reports in pregnancy are case series, with limited insight into population prevalence [1-5]. Reports from New York City described an alarming rate of asymptomatic SARS-CoV-2 PCR-positive pregnant patients (13.7-14.5%) [6, 7]. Although Washington State was among the first to confirm community transmission [8], our regional epidemic appears to be slowing with early public health response and widespread testing availability [9]. On March 2, 2020, University of Washington (UW) Department of Laboratory Medicine obtained Emergency Use Authorization (EUA) for a laboratory-developed SARS-CoV-2 test. Initial testing at UW Medicine focused on symptomatic persons under investigation (PUI), transitioning to universal testing of labor and delivery (L&D) and pre-surgical patients March 29, 2020. We present results of L&D SARS-CoV-2 PCR testing March 2, 2020-April 15, 2020, encompassing targeted and universal approaches.

Methods
Study design and patients
We performed a retrospective cohort study of SARS-CoV-2 PCR testing of L&D patients at UW Medical Center, Montlake and Northwest campuses. UW Montlake Labor and Delivery unit is a tertiary referral center for high-acuity obstetrical care with ~1850 deliveries per year and cesarean delivery rate of 46%. UW Northwest Birth Center has ~1100 deliveries annually of primarily uncomplicated pregnancies with cesarean delivery rate of 26%. Patients tested for SARS-CoV-2 March 2, 2020-April 15, 2020 were included.

Universal testing strategy
UW Montlake initiated universal testing for L&D inpatients March 24, 2020, followed by full implementation including outpatient screening of planned admissions March 29, 2020. UW Northwest implemented universal testing April 2, 2020. Both campuses had on-site rapid testing available starting March 30, 2020, preferentially utilized for L&D. After rapid testing instrument failure April 4, 2020, UW Northwest reverted to routine testing exclusively. Under universal testing, patients were tested as outpatients, primarily at a drive-through testing center within 48-72 hours of
planned admission, or upon hospital admission. Outpatient testing utilized routine assays located at
the off-site centralized UW Virology Laboratory. Patients underwent repeat testing if no result was
available within 72 hours of expected delivery or procedure. Known COVID-19 patients underwent
repeated testing on admission even if recovered, to facilitate return to standard precautions and
personal protection equipment (PPE) stewardship.

**SARS-CoV-2 testing**

Routine centralized UW Virology Laboratory testing utilized one of three RT-PCR assays depending
on instrument availability: Washington state EUA UW CDC-based laboratory-developed SARS-CoV-2
test (UW LDT), or FDA authorized Hologic Panther Fusion or Roche cobas SARS-CoV-2 tests. On-site
rapid testing utilized the DiaSorin Simplexa (MDX Liaison) EUA assay with run time of 75-90 minutes
(see Supplemental materials: SARS-CoV-2 test targets and interpretation).

**Data Collection**

Eligible patients were identified from outpatient and admission logs of pregnant and postpartum
patients. Sociodemographic and clinical characteristics were abstracted from medical records. Test
results were queried from UW Laboratory Medicine data warehouse. Data were entered into
Research Electronic Data Capture (REDCap, Vanderbilt University, Nashville, Tennessee, USA) and
analyzed with STATA version 15. UW Institutional Review Board approved study procedures under a
waiver of informed consent.

**Outcomes and Statistical Analysis**

Patient and testing characteristics were summarized by proportions and medians with interquartile
range (IQR) as appropriate. Testing results were characterized as positive, negative, or inconclusive.
Results

Between March 2, 2020-April 15, 2020, 230 pregnant and postpartum patients underwent SARS-CoV-2 testing; 42 (18.3%) under the initial targeted symptomatic PUI approach, and 188 (81.7%) under universal testing (Figure).

Supplemental Table 1 summarizes sociodemographic characteristics, pregnancy status, location and indication of testing. Among 224 pregnant (median gestational age 37.4 weeks [IQR 32.9-39.1], and 6 postpartum patients (median postpartum age 1.3 weeks [IQR 0.0-3.6], median age was 32 years [IQR 29-35]). Eighty-nine (38.7%) initially tested as outpatients, including 63 (70.8%) with drive-through testing, 16 (7.0%) during emergency room/obstetric triage evaluation not requiring admission, and 125 (54.4%) during admission. More than half of hospitalizations at initial testing were for L&D (66 [52.8%]), followed by antenatal (52 [41.6%]), outpatient/same day procedures (3 [2.4%]), and postpartum admissions (2 [1.6%]).

One hundred and eighty-four (80.0%) patients had a pregnancy outcome during the study period; 172 (74.8%) resulted in live birth, 3 (1.3%) fetal or neonatal demise, 8 (3.5%) termination of pregnancy, 1 (0.4%) spontaneous abortion, while 46 (20.0%) remained pregnant.

Results of SARS-CoV-2 testing

SARS-CoV-2 prevalence among symptomatic patients during initial targeted PUI screening (19.1% [8/42]) and after universal screening (22.2% [4/18]) were similar (Figure). Among 170 asymptomatic patients tested under universal screening, one tested positive and one inconclusive, with repeat testing at 24 hours negative for both. The asymptomatic positive patient’s initial positive test had cycle threshold near the detection limit and was negative when retested 24 hours later. Neither patient developed symptoms during the study period.

Thirty patients (13%) underwent repeat testing with 45 additional tests performed (Supplemental Table 2). Additional testing indication included: 6 (13.3%) symptomatic PUI (with negative results), 19 (42.2%) known SARS-CoV-2 positive, 2 (4.3%) previously inconclusive, and 18 (40.0%) for universal screening of asymptomatic patients. Nine patients with initial positive tests underwent retesting;
seven had at least one additional positive test, including six initially symptomatic patients who remained PCR-positive for ≥2 weeks (Figure 1). No patient with an initial negative or inconclusive test subsequently tested positive.

Among 275 total tests performed, 193 (70.2%) were tested by routine and 82 (29.8%) by rapid test. Median turn-around time was 2.5 hours (IQR 2.0-3.1) for rapid, and 7.1 hours (IQR 5.5-9.3) for routine tests (aggregate data reported; disaggregated initial and repeat testing reported in Supplemental Table 1, 2).

Discussion

We found low prevalence of SARS-CoV-2 among L&D patients after initiating universal screening. Universal testing was accomplished using a combination of on-site rapid testing, high throughput centralized testing, and outpatient drive-through screening prior to admission. This multipronged approach ensured almost all patients had a known SARS-CoV-2 status prior to delivery or procedure, including patients with precipitous labor or requiring emergent/urgent procedures. Among a small subset of PCR-positive patients retested, a high proportion remained positive for ≥2 weeks. While rapid testing aided in short turn-around times, routine testing provided results within 8 hours, further improved to ~6 hours by study end as laboratory capacity increased. This approach was feasible and yielded valuable real-time data on SARS-CoV-2 status enabling judicious PPE use.

Our study has some similar features to recent reports from New York including universal screening of all L&D patients [6, 7], however, prevalence of confirmed SARS-CoV-2 among both symptomatic and asymptomatic patients differed substantially. The positive rate for symptomatic PUI screening in our study was 19.1-22.2%, in contrast to reported rates of 68.8% (11/16) and 100% (4/4) in New York [6, 7]. Only 1.2% of asymptomatic women tested positive or inconclusive for SARS-CoV-2 in our study, compared to 13.7-14.5% in New York reports, and neither patient was positive upon retesting at 24 hours. Our lower SARS-CoV-2 prevalence among pregnant and postpartum patients likely reflects local epidemic dynamics including potentially earlier community spread, but currently lower
prevalence within our region. We estimate the average population prevalence in greater Seattle and King County between March 23 and April 9, 2020 was 0.24% [95% CI 0.05% - 0.75%], with evidence of continued decline [9].

PCR-based diagnostics are limited in their ability to differentiate infectious SARS-CoV-2 virus from persistent viral shedding in the setting of clinically recovered COVID-19 that likely poses a markedly decreased risk of person-to-person transmission. While we routinely retest known COVID-19 patients on admission and prior to procedures to inform infection prevention practice, the clinical significance of persistently positive PCR in the setting of clinical improvement including among L&D patients in unknown [10]. Our institutional practice is to maintain COVID-precautions using a test-based strategy, and counsel patients per CDC guidance that that the risk of transmission is substantially reduced after 10 days of symptom onset and >72 hours after symptom resolution [11].

Universal SARS-CoV-2 testing of pregnant and postpartum patients occurred in conjunction with all pre-surgical patients, to reduce risk of SARS-CoV-2 transmission from intubation for general anesthesia, an aerosol-generating procedure. The pre-surgical universal SARS-CoV-2 screening policy was extended to L&D patients with the rationale that many require cesarean delivery or other surgical procedures and may potentially require urgent general anesthesia. Our cesarean delivery rates of 26-46% illustrate the frequency of surgery during a delivery hospitalization. The American College of Obstetricians and Gynecologists recently strengthened their recommendations regarding testing on L&D units [12]. Our current institution-wide screening approach continues to evolve in response to local epidemiology and testing availability, and now includes universal screening of all hospital admissions. Our most recent estimates suggest <1% of asymptomatic patients have tested positive since initiating universal screening. Early adoption of universal screening (starting with surgical and L&D patients) allowed data-driven decisions to be made informing PPE use to ensure protection of patients and health care workers, including L&D-related units (i.e. newborn nursery and neonatal intensive care unit). Further, this information aided in counseling regarding risks and
benefits of infant separation/co-location and breastfeeding practices, utilizing a shared-decision making approach. Despite low numbers of additional cases identified, universal screening of pregnant patients provides important surveillance information due to the representativeness of this population to the greater community.
AUTHOR CONTRIBUTIONS: SML, AK, LS, MB, AM, KAW, JH drafted the initial manuscript. All authors reviewed, contributed to revision, and approved the final manuscript.

ACKNOWLEDGEMENTS We would like to acknowledge several individuals for their support of this project: Nicole Wothe and Brian Reed for administrative support, Jaclyn Escudero for assistance with figures, Grace John-Stewart for editorial advice, Ashleigh Lewis for REDCap assistance, and Loren Balcom and Melissa Habrat for assistance with data and honest broker review, respectively. We also thank the Washington State COVID-19 in Pregnancy Collaborative, which helped to provide infrastructure for chart abstraction.

DECLARATION OF INTEREST: A.K. has been a consultant for Pfizer and GlaxoSmithKline outside the submitted work. A.L.G. reports personal fees from Abbott Molecular outside the submitted work. The other authors have no conflicts of interest to declare.

ROLE OF FUNDING SOURCE: The corresponding author had full access to the manuscript and had final responsibility for the decision to submit for publication. The authors report no conflicts of interest. This work was supported by the National Institute of Allergy and Infectious Diseases (grant numbers AI133976, AI145890, AI144938 and AI143265 to KAW and AI120793 to SML). Study data were managed using a REDCap electronic data capture tool hosted by the Institute of Translational Health Sciences at the University of Washington, which was supported by the National Center for Advancing Translational Sciences (UL1TR002319). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other funders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
REFERENCES


Figure 1

Study flow of SARS-CoV-2 screening among pregnant and postpartum patients

Panel A: Study flow of pregnant and postpartum patients screened for SARS-CoV-2 prior to and after initiation of universal screening in Seattle, Washington. Figure includes results of initial testing only. Among 230 patients, there were 275 tests performed. Results of repeat testing are detailed in Supplemental Table 2.

Panel B: Results of repeat SARS CoV-2 testing among initially positive pregnant patients. Timing denotes first and last test performed during the study period by either gestational age (GA) or postpartum (PP) age.

Figure: SARS-CoV-2 screening among pregnant and postpartum patients in the UW Medicine system, Seattle, Washington. Panel A: Study flow of pregnant and postpartum patients screened for SARS-CoV-2 prior to and after initiation of universal screening in Seattle, Washington. Figure includes results of initial testing only. Among 230 patients, there were 275 tests performed. Results of repeat testing are detailed in Supplemental Table 2. Panel B: Results of repeat SARS CoV-2 testing among initially positive pregnant patients. Timing denotes first and last test performed during the study period by either gestational age (GA) or postpartum (PP) age.